Literature DB >> 32279715

Medical, Surgical, and Genetic Treatment of Huntington Disease.

Christine M Stahl1, Andrew Feigin2.   

Abstract

Huntington disease, a neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, is caused by a CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4. Current treatments target symptom management because there are no disease-modifying therapies at this time. Investigation of RNA-based and DNA-based treatment strategies are emerging and hold promise of possible future disease-modifying therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antipsychotic drugs; Antisense oligonucleotides; Deep brain stimulation; Huntington disease; Vesicular monoamine transporter type 2 inhibitors

Year:  2020        PMID: 32279715     DOI: 10.1016/j.ncl.2020.01.010

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  5 in total

Review 1.  Huntington's Disease: New Frontiers in Therapeutics.

Authors:  Ling Pan; Andrew Feigin
Journal:  Curr Neurol Neurosci Rep       Date:  2021-02-14       Impact factor: 5.081

2.  Novel Substituted Heterocyclic and Heteroaryl Compounds for Treating Huntington's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-07-20       Impact factor: 4.632

3.  Novel Substituted Benzothiazole Compounds for Treating Huntington's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-03-31       Impact factor: 4.345

4.  Novel Substituted Monocyclic Heteroaryl Compounds for Treating Huntington's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

Review 5.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.